October 2024 Issue
Journey alongside Pharmaron as we embrace the latest advancements to fast-track drug discovery for small molecules and other emerging modalities.
DMPK
Minimal Lead Times for PK Studies
Large animals are readily available for PK testing at Pharmaron, enabling industry-leading lead times thanks to our global presence, in-house animal colonies, and flexible workforce.
Drug Discovery
Expertise in Targeted Protein Degradation
Protein degradation discovery requires a team of scientists experienced with this compound group's complex nature and mechanism of action.
Our comprehensive service platform covers every step, from idea to IND.
in vivo Pharmacology
Access to a Wide Range of Disease Models
With over 2,000 animal models offered for in vivo testing in the US and China, we enable clients to comprehensively evaluate compounds across various therapeutic areas like oncology, metabolic disorders, neurology, inflammation, pain, ophthalmology, and more.
NEWS
Drug Design
Structure-Guided Design of a new KMT9 Inhibitor
Pharmaron’s integrated drug discovery team provided medicinal chemistry support in designing a new inhibitor of methyltransferase KMT9 (KMI169), aimed at therapy-resistant prostate cancer.
Pharmacokinetics
Infusion for Controlled Drug Delivery
Our teams in China, the UK, and the US routinely provide controlled delivery of drugs via IV infusion for short- and long-term studies on small and large animal species.
in vitro Biology
Organoids from Patient-Derived Xenografts
Our biobank comprises over 140 PDXO models available for testing, focusing on generating results that mimic patient-to-patient variability. Our case study shows how we use PDXO models for drug resistance analysis.
INSIDE PHARMARON
DMPK
Working hand-in-hand with the FDA: Studying Bioequivalence in vitro via IDAS
Pharmaron works closely with regulatory authorities such as the FDA, EMA, MHRA, and others. We support the preparation and filing of regulatory submissions for our clients. Similarly, the FDA draws from our experience in using predictive in vitro models.
For example, a recent FDA-funded study examined the impact of antioxidants, a common mitigation strategy to limit the formation of nitrosamines, on the permeability of BCS Class III model drugs using our In Vitro Dissolution Absorption System (IDAS).
UPCOMING
DMPK Webinar Series
DMPK and Bioanalytical Strategies for the Successful Development of Antibody-Drug Conjugates (ADCs)
ADCs combine the targeting capabilities of antibodies with the potent cytotoxic effects of small molecule drugs. This dual nature necessitates specific strategies for discovering and developing ADCs, paving the way for accelerated clinical development. This webinar discusses: